Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.45 |
| ▸ | FAP | Q12884 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539508 | 0.86 | DPP4 (0.36) | DPP4DPP7FAPHPGD | |
| SCHEMBL28149214 | 0.81 | DPP4 (0.47) | DPP4DPP7FAPNAMPTDPP8 | |
| SCHEMBL30971694 | 0.80 | — | — | |
| SCHEMBL15701184 | 0.79 | DPP4 (0.46) | DPP4DPP7FAPNAMPTDPP8 | |
| SCHEMBL4830838 | 0.79 | DPP4 (0.46) | DPP4DPP7FAPNAMPTDPP8 | |
| SCHEMBL20221436 | 0.78 | DPP4 (0.46) | DPP4DPP7FAPNAMPTDPP8 | |
| SCHEMBL32675753 | 0.77 | DPP4 (0.38) | DPP4DPP7FAPNAMPT | |
| SCHEMBL31143234 | 0.77 | DPP4 (0.45) | DPP4DPP7FAPNAMPTDPP8 | |
| SCHEMBL3116395 | 0.77 | DPP4 (0.45) | DPP4DPP7FAPNAMPTDPP8 | |
| SCHEMBL8029490 | 0.77 | DPP4 (0.45) | DPP4DPP7NAMPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | PARDES BIOSCIENCES INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4387980-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023023631-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023631-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20070265261-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070265261-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070265261-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| EP-1791817-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2005121089-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121089-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CPN1, CTSL | DPP4 124/4885DPP7 103/4885FAP 300/4885 |
| US-20070265261-A1 | Dpp-IV Inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885FAP 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.